[go: up one dir, main page]

CA2402865A1 - Formulations opioides - Google Patents

Formulations opioides Download PDF

Info

Publication number
CA2402865A1
CA2402865A1 CA002402865A CA2402865A CA2402865A1 CA 2402865 A1 CA2402865 A1 CA 2402865A1 CA 002402865 A CA002402865 A CA 002402865A CA 2402865 A CA2402865 A CA 2402865A CA 2402865 A1 CA2402865 A1 CA 2402865A1
Authority
CA
Canada
Prior art keywords
fentanyl
pain
formulation
drug
pharmaceutical formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002402865A
Other languages
English (en)
Inventor
Dana Litmanovitz
Barbara J. F. Laidlaw
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Durect Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2402865A1 publication Critical patent/CA2402865A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne des formulations à teneur élevée en opioïdes, notamment le fentanyl ou les congénères de fentanyl. La formulation de cette invention contient du fentanyl ou un congénère de fentanyl dans des proportions particulièrement élevées par rapport aux formulations classiques, par exemple, dans l'ordre d'environ 2 fois à environ 10 000 supérieures aux formulations classiques, notamment, les formulations actuellement disponibles dans le commerce. Ces formulations sont particulièrement utiles dans le cadre d'une administration à long terme à un sujet souffrant de douleur. En outre, cette invention concerne des dispositifs d'administration de médicaments renfermant ces formulations à teneur élevée en opioïdes, et concerne également des méthodes permettant d'atténuer la douleur chez un sujet, consistant à lui administrer ces formulations à teneur élevée en opioïdes.
CA002402865A 2000-03-10 2001-03-02 Formulations opioides Abandoned CA2402865A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18826300P 2000-03-10 2000-03-10
US60/188,263 2000-03-10
PCT/US2001/006955 WO2001068140A2 (fr) 2000-03-10 2001-03-02 Formulations opioides

Publications (1)

Publication Number Publication Date
CA2402865A1 true CA2402865A1 (fr) 2001-09-20

Family

ID=22692427

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002402865A Abandoned CA2402865A1 (fr) 2000-03-10 2001-03-02 Formulations opioides

Country Status (4)

Country Link
JP (1) JP4969009B2 (fr)
AU (2) AU4341401A (fr)
CA (1) CA2402865A1 (fr)
WO (1) WO2001068140A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0300531D0 (en) 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
EP1807018A4 (fr) * 2004-10-21 2012-07-04 Univ Iowa Res Found Systeme d'administration in situ de medicaments a liberation controlee
US20140179740A1 (en) * 2012-12-21 2014-06-26 Mylan Inc. Stable liquid remifentanil formulations
JP6081240B2 (ja) * 2013-03-13 2017-02-15 テルモ株式会社 レミフェンタニル注射液剤
EP3192509B1 (fr) 2014-09-12 2021-03-31 Terumo Kabushiki Kaisha Injection de rémifentanil
KR20210113439A (ko) * 2016-10-31 2021-09-15 테이코쿠 팔마 유에스에이, 인코포레이티드 덱스메데토미딘 경피 전달 장치를 이용한 통증을 관리하는 방법

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4588580B2 (en) * 1984-07-23 1999-02-16 Alaz Corp Transdermal administration of fentanyl and device therefor
ZA856002B (en) * 1984-08-10 1987-04-29 Du Pont Transdermal delivery of opioids
GB8900267D0 (en) * 1989-01-06 1989-03-08 Riker Laboratories Inc Narcotic analgesic formulations and apparatus containing same
JPH05331064A (ja) * 1992-05-26 1993-12-14 Sekisui Chem Co Ltd 消炎鎮痛貼付剤
JPH07206903A (ja) * 1994-01-24 1995-08-08 Takeda Chem Ind Ltd 超分子構造型集合体
EP0759744B1 (fr) * 1994-05-13 2001-10-17 Aradigm Corporation Formulation en aerosol contenant un narcotique
JPH09176000A (ja) * 1995-12-28 1997-07-08 Teijin Ltd 医療用貼付剤
JP2000512649A (ja) * 1996-06-27 2000-09-26 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 徐放性スフェンタニル組成物
US6541021B1 (en) * 1999-03-18 2003-04-01 Durect Corporation Devices and methods for pain management

Also Published As

Publication number Publication date
JP4969009B2 (ja) 2012-07-04
AU4341401A (en) 2001-09-24
AU2001243414B2 (en) 2005-05-19
WO2001068140A2 (fr) 2001-09-20
WO2001068140A3 (fr) 2001-12-13
JP2003526680A (ja) 2003-09-09

Similar Documents

Publication Publication Date Title
AU769314B2 (en) Devices and methods for pain management
US20110136847A1 (en) High Concentration Formulations of Opioids and Opioid Derivatives
US6835194B2 (en) Implantable devices and methods for treatment of pain by delivery of fentanyl and fentanyl congeners
US20140350053A1 (en) Opioid formulations
AU2002323569A1 (en) Implantable devices and methods for treatment of pain by delivery of fentanyl and fentanyl congeners
WO2001043528A2 (fr) Methodes et procedes d'administration de morphine-6-glucuronide par voie intracephalorachidienne
AU2001243414B2 (en) Opioid formulations
AU2001243414A1 (en) Opioid formulations

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead